High levels of argininosuccinic acid are expected in colorectal cancer since almost all CRC subtypes present argininosuccinate synthase [39], an adaptation of the cancer cells to synthesize arginine starting from citrulline, with targeting arginine metabolism being an avenue explored for its potential in CRC treatment [40]. This evidence concerns the gene ASS1 and colorectal cancer.